Plain-English translation of NCT06357533 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing (a new targeted cancer drug) combined with another medication called , compared to standard immunotherapy, for people with advanced non-squamous lung cancer. The trial focuses on patients whose cancer has a specific marker (high PD-L1 expression) and doesn't have certain genetic changes. Researchers want to see if these new medication combinations can help patients live longer and healthier than the current standard treatment.
Many people with advanced lung cancer who have this specific marker don't respond well enough to current standard immunotherapy alone. This trial exists to find out whether combining newer targeted drugs with different approaches might give patients better outcomes and longer survival.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive one of three treatments given by intravenous infusion (IV) every 3 weeks. Each treatment cycle lasts 21 days, with your medication given on day 1 of each cycle. You will have regular clinic visits for blood tests, scans, and physical exams to monitor how well the treatment is working and check for side effects. The trial will continue until the medication stops working, you develop unmanageable side effects, or you decide to leave the study.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
United States